Valuation : Defence Therapeutics Inc.

Market Cap 33.35M 24M 20.68M 19.39M 17.7M 2.29B 33.45M 230M 89.76M 1.16B 90.11M 88.15M 3.84B P/E 2024
-2.5x
P/E 2025 -9.9x
Enterprise Value 33.62M 24.2M 20.85M 19.55M 17.85M 2.31B 33.73M 232M 90.49M 1.17B 90.85M 88.87M 3.87B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
66.13%
Yield 2024 *
-
Yield 2025 -
1 day+1.96%
1 week+1.96%
Current month+30.00%
1 month+23.81%
3 months-3.70%
6 months-14.75%
Current year-27.78%
1 week 0.5
Extreme 0.5
0.56
1 month 0.37
Extreme 0.37
0.59
Current year 0.36
Extreme 0.365
0.74
1 year 0.36
Extreme 0.365
0.93
3 years 0.36
Extreme 0.365
3.04
5 years 0.36
Extreme 0.365
8.15
10 years 0.36
Extreme 0.365
8.15
Manager TitleAgeSince
Chief Executive Officer - 01/08/2026
Director of Finance/CFO 55 20/12/2024
Chief Operating Officer - 17/08/2026
Director TitleAgeSince
Chairman 53 01/08/2026
Director/Board Member 64 05/01/2021
Director/Board Member - 27/09/2024
Date Insider Type Main position Quantity % Market Cap.
8/1/26 A Option

Chief Executive Officer

200,000 0.2639%
8/1/26 A Option

Founder

200,000 0.2639%
6/3/26 A Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.96%-31.58%-80.95% 28.37M
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.18%-0.76%+67.60%+93.46% 27.46B
Weighted average by Cap. -1.70%-1.06%+95.70%+133.60%

Financials

2024 2025
Net sales - -
Net income -13.19M -9.5M -8.18M -7.67M -7M -908M -13.24M -91.02M -35.51M -458M -35.65M -34.88M -1.52B -3.52M -2.53M -2.18M -2.05M -1.87M -242M -3.53M -24.3M -9.48M -122M -9.52M -9.31M -406M
Net Debt 1.69M 1.22M 1.05M 983K 897K 116M 1.7M 11.66M 4.55M 58.68M 4.57M 4.47M 195M 272K 196K 169K 158K 144K 18.7M 273K 1.88M 732K 9.44M 735K 719K 31.3M
Logo Defence Therapeutics Inc.
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.
Employees
-
Date Price Change Volume
28/08/26 CA$0.5200 +1.96% 24,620
27/08/26 CA$0.5100 -5.56% 19,000
26/08/26 CA$0.5400 +5.88% 45,808
25/08/26 CA$0.5100 +2.00% 89,650
24/08/26 CA$0.5000 -1.96% 137,584